The updated guidance, which was largely driven by lower-than-anticipated sales of GLP-1 blockbusters Mounjaro and Zepbound, ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates. It was the ...

Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its ...

Eli Lilly's dominance in the GLP-1 market and strong revenue growth forecast make LLY stock a promising investment, with a ...

Investors can strategize their portfolio with Multiplo Picks, a selection of 10 stocks based on the overvalued American ...

And according to the company's 10Q filing, "the majority of our online revenue is subscription ... tirzepatide -- the main ingredient in Mounjaro and Zepbound -- from its shortage list.

Mounjaro is a GLP-1 inhibitor developed to help people with diabetes regulate their blood glucose. Elon Musk, the 53-year-old CEO of Tesla and SpaceX, recently shared a festive image of himself ...

Musk elaborated in a follow-up post he is technically using the Eli Lilly weight-loss drug Mounjaro over Novo Nordisk’s Ozempic, “but that doesn’t have the same ring to it.” The post comes ...

tirzepatide — the active ingredient in Zepbound and its counterpart Mounjaro for diabetes — is fully available again. "FDA has determined that the shortage of tirzepatide injection products ...

Mounjaro, a competitor, was approved for weight loss in November 2023 under the separate name Zepbound. It will be rolled out on a limited basis on the NHS in the UK from April. It has been nickna ...

agonists such as Mounjaro, Zepbound, Ozempic, and Wegovy -- all of which are used for either diabetes treatment or chronic weight management. Where to invest $1,000 right now? Our analyst team ...

Despite the post labeled with Ozempic, Musk admitted in the comments that it is actually Mounjaro that he has taken ... gems in the stock market using our proprietary data and pattern recognition ...